Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients

Simple item page
dc.contributor.authorGonul A.S.
dc.contributor.authorAkdeniz F.
dc.contributor.authorTaneli F.
dc.contributor.authorDonat O.
dc.contributor.authorEker Ç.
dc.contributor.authorVahip S.
dc.date.accessioned2024-07-22T08:23:37Z
dc.date.available2024-07-22T08:23:37Z
dc.date.issued2005
dc.description.abstractResearchers have reported that serum brain-derived neurotrophic factor (sBDNF) of drug-free depressed patients are lower than those of healthy controls and proposed that low sBDNF levels might reflect failure of neuronal plasticity in depression. In this study, we compared sBDNF levels of depressed patients (n = 28) before and after 8 weeks of antidepressant treatment, with those of healthy controls (n = 18) to test the hypothesis that initially low sBDNF levels of drug-free depressed patients will increase parallel with their clinical response to antidepressant treatment. The severity of depression and response to treatment were assessed with Hamilton Rating Scale for Depression (HAM-D). sBDNF was assayed with the sandwich ELISA method. Baseline sBDNF levels of patients (mean, 20.8 ng/ml; [S. D., 6.7]) were significantly lower than those of controls (mean, 26.8 ng/ml; [S. D., 9.3]; p = 0.015), and were negatively correlated with HAM-D scores (r = -0.49, p = 0.007). After 8 weeks of treatment, sBDNF levels of patients had increased significantly (mean, 33.3 ng/ml; [S. D., 9.9]; p < 0.001) and no longer differed from those of controls. These results support the hypothesis that BDNF might play a critical role in the pathophysiology of major depressive disorder and successful antidepressant treatment increases the attenuated BDNF levels in depressed patients.
dc.identifier.DOI-ID10.1007/s00406-005-0578-6
dc.identifier.issn09401334
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19616
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAntidepressive Agents
dc.subjectBrain-Derived Neurotrophic Factor
dc.subjectDepressive Disorder, Major
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPsychiatric Status Rating Scales
dc.subjectantidepressant agent
dc.subjectbrain derived neurotrophic factor
dc.subjectcitalopram
dc.subjectfluoxetine
dc.subjectserotonin uptake inhibitor
dc.subjectsertraline
dc.subjectvenlafaxine
dc.subjectadult
dc.subjectarticle
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectdepression
dc.subjectdisease severity
dc.subjectdrug effect
dc.subjectdrug response
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectHamilton scale
dc.subjecthuman
dc.subjectmale
dc.subjectpriority journal
dc.subjectscoring system
dc.subjectstatistical significance
dc.subjecttreatment outcome
dc.titleEffect of treatment on serum brain-derived neurotrophic factor levels in depressed patients
dc.typeArticle

Files

Collections

Scopus Koleksiyonu